PLANO, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, Diron Smith, Vice President and Interim Chief Financial Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development & Investor Relations, are scheduled to participate at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023 at 1:30 p.m. ET.
A live webcast of the presentation will be available through Integer’s investor relations website at investor.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: | |
| Andrew Senn | Kelly Butler | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$116.98 |
| Daily Change: | 0.77 0.66 |
| Daily Volume: | 806,507 |
| Market Cap: | US$3.920B |
March 18, 2025 March 12, 2025 February 20, 2025 February 18, 2025 February 03, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
